Mr Hiromi Yoshikawa, executive senior managing director, Otsuka Pharmaceutical Factory, said, "Our partnership with LCT in DIABECELL has delivered on all fronts in the last year. NTCELL represents another pioneering potential therapeutic that LCT has developed. We are delighted to extend our partnership to include NTCELL so that together we might transform the lives of patients with Parkinson's disease and other neurological disorders."

Mr Roy Austin, chairman, LCT, added, "That Otsuka has chosen to expand its partnership with LCT is a testament to the mutual respect and trust that the two companies have for each other, and to the progress we have made in the last year. It further validates LCT's approach to innovative research, clinical development and business development, and enables us to continue to build LCT into a biopharmaceutical company with a diverse platform of technologies and therapeutic assets."